<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589290</url>
  </required_header>
  <id_info>
    <org_study_id>080033</org_study_id>
    <secondary_id>08-C-0033</secondary_id>
    <nct_id>NCT00589290</nct_id>
    <nct_alias>NCT00720187</nct_alias>
  </id_info>
  <brief_title>Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage</brief_title>
  <official_title>A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

        -  Cisplatin-containing chemotherapy is the standard treatment for advanced tumors of the
           thymus that cannot be removed surgically.

        -  New treatment options are needed for patients with advanced tumors of the thymus that do
           not improve with cisplatin-containing therapy.

        -  Belinostat is a drug that inhibits enzymes called histone deacetylase. Histone
           deacetylase inhibitors have shown promising activity in many cancers and may be useful
           in treating patients with thymic tumors.

      Objectives:

      -To assess the safety and effectiveness of belinostat for treatment of malignant thymic
      tumors in patients who failed after standard treatment.

      Eligibility:

      -Patients 18 years of age or older with an advanced thymic tumor that has progressed after
      treatment with platinum-containing chemotherapy.

      Design:

        -  Patients receive belinostat treatment in 21-day cycles. The drug is given as an infusion
           through a vein during days 1 through 5 of each cycle. Treatment cycles continue as long
           as the medicine is tolerated and the cancer does not worsen.

        -  Patients have a physical examination and several blood tests during every cycle.

        -  Patients have an electrocardiogram every cycle before starting the belinostat infusion
           and again on the last day of the infusion.

        -  Patients undergo computed tomography (CT) or other imaging test, such as ultrasound or
           MRI, every two cycles to evaluate the response of the tumor to treatment.

        -  Tumor tissue obtained from a previous biopsy is used for research purposes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Cisplatin-containing chemotherapy is the standard of care for advanced unresectable thymoma
      and thymic carcinoma. New options for treatment are necessary in patients with advanced
      thymoma and thymic carcinoma that have progressed on cisplatin-containing therapy. Histone
      deacetylase inhibitors have shown promising clinical activity in many malignancies.
      Belinostat, a potent histone deacetylase inhibitor, is a promising agent, which may have
      activity in patients with thymic malignancies.

      Objectives:

        -  To assess objective response rate according to the Response Evaluation Criteria in Solid
           Tumors (RECIST) criteria for belinostat monotherapy.

        -  To assess safety of belinostat.

        -  To evaluate time to response, duration of response, progression-free survival and
           overall survival.

        -  To identify chromosomal gains or losses and gene methylation status by comparative
           genomic hybridization and methylation microarrays in thymoma / thymic carcinomas in
           relation to clinical outcome.

        -  To assess expression levels of particular proteins on the pretreatment tumor sample, by
           immunohistochemistry (IHC) and correlate them with clinical outcome.

        -  To identify and measure changes in p21 and protein hyperacetylation in peripheral blood
           mononuclear cells (PBMC), and vascular endothelial growth factor (VEGF) and basic
           fibroblast growth factor (bFGF) in plasma and correlate them with clinical outcome.

        -  To measure changes in modulation of T-cell function in peripheral blood lymphocytes.

      Eligibility:

        -  Patients with histologically confirmed thymic carcinoma or thymoma who have previously
           been treated on at least one platinum containing chemotherapy regimen.

        -  Measurable disease by RECIST criteria.

        -  Adequate renal, hepatic and hematopoietic function.

        -  QT Interval must be less than 500 msec at baseline by electrocardiogram (EKG)
           (Fridericia's formula used for correction).

        -  No major surgery, radiotherapy, or chemotherapy within 28 days of belinostat therapy.

      Design:

        -  Patients will receive belinostat as a 30-minute intravenous (IV) infusion of 1000
           mg/m^2/day during days 1-5 every 3 weeks. After 12 cycles of treatment, cycles will be
           given every 4 weeks.

        -  Treatment with belinostat alone will continue until disease progression.

        -  Toxicity will be assessed every cycle by the Common Terminology Criteria for Adverse
           Events (CTCAE) Version 3.0 until December 31, 2010, and by CTCAE Version 4.0 beginning
           January 1, 2011.

        -  Tumor response assessments by RECIST criteria will be performed every 2 cycles. After 12
           cycles, response assessment will be every 3 cycles.

        -  Correlative studies including comparative genomic hybridization, methylation microarray
           analysis, and tissue immunohistochemistry studies will be done on existing tumor blocks.

        -  Blood samples for circulating plasma biomarkers of response including VEGF will be drawn
           the first day of cycle 1 and 2 as well as cycle 1, day 3.

        -  Blood samples for protein hyperacetylation and T cell modulation analyses will be drawn
           the first day of cycle 1 and 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Partial Response</measure>
    <time_frame>25.5 months</time_frame>
    <description>Response is defined by the Response Evaluation Criteria in Solid Tumor (RECIST). Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. For additional details about the RECIST criteria see the protocol Link module.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chromosomal Gains or Losses in Comparative Genomic Hydridization in Thymoma and Thymic Cancer</measure>
    <time_frame>46 months</time_frame>
    <description>Utilize a patients tumor tissue to determine if there is any correlation between chromosomal gains or losses in comparative genomic hybridization in thymoma and thymic carcinomas and clinical outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>26 months</time_frame>
    <description>Here are the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Thymoma</condition>
  <condition>Thymic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Belinostat Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belinostat (PDX101)</intervention_name>
    <description>1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.</description>
    <arm_group_label>Belinostat Treatment</arm_group_label>
    <other_name>PDX101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Histologically confirmed invasive recurrent or metastatic thymoma or thymic carcinoma by
        the pathology department / Center for Cancer Research (CCR) / National Cancer Institute
        (NCI).

        Patients must have had at least one prior platin-containing chemotherapy regimen. There is
        no limit to the number of prior chemotherapy regimens received. Progressive disease should
        have been documented before entry into the study.

        Patients must have measurable disease, defined as at least one lesion that can be
        accurately measured in at least one dimension (longest diameter to be recorded) as greater
        than 20 mm with conventional techniques or as greater than 10 mm with spiral computed
        tomography (CT) scan.

        Patients must have recovered from toxicity related to prior therapy to at least to grade 1
        (defined by the Common Terminology Criteria for Adverse Events (CTCAE) 3.0 until December
        31, 2010, and by CTCAE 4.0 beginning January 1, 2011) and must not have had prior
        chemotherapy within 4 weeks. Patients must be at least 28 days since any prior radiation or
        major surgery.

          -  Target lesions cannot be selected within previously irradiated areas, if not newly
             arising or clearly progressing after irradiation as proven by repeat scanning.

          -  Concurrent corticosteroids for myasthenia gravis, or other paraneoplastic syndromes,
             or other chronic conditions are allowed.

        Age greater than 18 years.

        Life expectancy of greater than 3 months.

        Performance status (Eastern Cooperative Oncology Group (ECOG)) less than or equal to 2.

        Patients must have adequate organ and marrow function (as defined below). Patients must
        have returned to base line or grade one from any acute toxicity related to prior therapy.

        Laboratory Test/Required Value:

        Absolute neutrophil count greater than 1,500/microl.

        Platelets greater than 100,000/microl.

        International normalized ratio (INR) less than or equal to 1.5 times upper limit of normal
        (ULN) or

        Partial thromboplastin time (PTT) abnormality can be explained by the presences of lupus
        anticoagulant or in the therapeutic range if on anticoagulation.

        Total bilirubin less than or equal to 1.5 times institutional upper limits of normal.

        Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase(SGOT) and alanine
        aminotransferase (ALT)/serum glutamic pyruvic transaminase(SGPT) less than or equal to 3
        times institutional upper limit of normal.

        Creatinine less than or equal to 1.5 times institutional upper limits of normal or
        Calculated Creatinine greater than 45 mL/min/1.73 m^2 for patients with creatinine.

        Clearance levels above institutional normal.

        The effects of belinostat on the developing human fetus at the recommended therapeutic dose
        are unknown. For this reason and because histone deacetylase (HDAC) inhibitors are known to
        be teratogenic, women of child-bearing potential and men must agree to use adequate
        contraception (hormonal or barrier method of birth control; abstinence) prior to study
        entry and for the duration of study participation and continue for at least 2 months after
        completion. Should a woman become pregnant or suspect she is pregnant while participating
        in this study, she should inform her treating physician immediately. Because there is an
        unknown but potential risk for adverse events in nursing infants secondary to treatment of
        the mother with belinostat, breastfeeding should be discontinued if the mother is treated
        with belinostat.

        Ability to comply with intravenous administration schedule, and the ability to understand
        and the willingness to sign a written informed consent document.

        EXCLUSION CRITERIA:

        Patients with symptomatic brain metastases should be excluded from this clinical trial
        because of their poor prognosis and because they often develop progressive neurologic
        dysfunction that would confound the evaluation of neurologic and other adverse events.
        However, patients who have had treatment for their brain metastases and whose brain
        metastatic disease status has remained stable for at least 3 months without steroids may be
        enrolled at the discretion of the principal investigator.

        Uncontrolled medical illness including, but not limited to, ongoing or uncontrolled,
        symptomatic congestive heart failure (American Heart Association (AHA) Class II or worse),
        uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, or psychiatric
        illness/social situations that would limit compliance with study requirements.

        Marked baseline prolongation of Q wave, T wave (QT)/corrected QT(QTc) interval, e.g.,
        repeated demonstration of a QTc interval greater than 500 msec (Fridericia's formula used
        for correction); Long QT Syndrome. Any concomitant medication that may cause QTc
        prolongation, induce Torsades de Pointes.

        Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral
        therapy are excluded from the study because of possible pharmacokinetic interactions with
        belinostat.(HIV) positive patients not receiving antiretroviral therapy are excluded due to
        the possibility that belinostat may worsen their condition and the likelihood that the
        underlying condition may obscure the attribution of adverse events with respect to
        belinostat.

        Patients may not be receiving any other investigational agents.

        History of another invasive malignancy in the last five years. Adequately treated
        non-invasive, non-melanoma skin cancers as well as in situ carcinoma of the cervix will be
        allowed.

        Prior treatment with drugs of the HDAC inhibitor class.

        Patients with tumor amenable to potentially curative therapy as assessed by the
        investigator.

        Subjects with resectable tumors would not be eligible for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Giaccone, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2008-C-0033.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>Medline Plus</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>Drug Information</description>
  </link>
  <link>
    <url>http://www.clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>United States Food &amp; Drug Administration Resources</description>
  </link>
  <link>
    <url>http://ctep.cancer.gov</url>
    <description>RECIST</description>
  </link>
  <reference>
    <citation>Giaccone G, Wilmink H, Paul MA, van der Valk P. Systemic treatment of malignant thymoma: a decade experience at a single institution. Am J Clin Oncol. 2006 Aug;29(4):336-44.</citation>
    <PMID>16891859</PMID>
  </reference>
  <reference>
    <citation>Wright CD. Management of thymomas. Crit Rev Oncol Hematol. 2008 Feb;65(2):109-20. Epub 2007 Jun 14. Review.</citation>
    <PMID>17570676</PMID>
  </reference>
  <reference>
    <citation>Giaccone G. Treatment of malignant thymoma. Curr Opin Oncol. 2005 Mar;17(2):140-6. Review.</citation>
    <PMID>15725919</PMID>
  </reference>
  <results_reference>
    <citation>Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, Trepel J, Lee MJ, Cao L, Espinoza-Delgado I, Spittler J, Loehrer PJ Sr. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011 May 20;29(15):2052-9. doi: 10.1200/JCO.2010.32.4467. Epub 2011 Apr 18.</citation>
    <PMID>21502553</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 25, 2007</study_first_submitted>
  <study_first_submitted_qc>December 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <results_first_submitted>October 28, 2011</results_first_submitted>
  <results_first_submitted_qc>April 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2012</results_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Arun Rajan, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Histone deacetylase (HDAC) Inhibitors</keyword>
  <keyword>Mediastinal Neoplasm</keyword>
  <keyword>Thymic Carcinoma</keyword>
  <keyword>Thymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Belinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study plans to accrue 1.85 patients per month. The expected accrual is 41 patients (25 thymoma and 16 thymic).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Belinostat Treatment</title>
          <description>1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Belinostat Treatment</title>
          <description>1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.53" spread="13.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Partial Response</title>
        <description>Response is defined by the Response Evaluation Criteria in Solid Tumor (RECIST). Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. For additional details about the RECIST criteria see the protocol Link module.</description>
        <time_frame>25.5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thymoma Patients</title>
            <description>Well differentiated neoplasm</description>
          </group>
          <group group_id="O2">
            <title>Thymic Patients</title>
            <description>Poorly differentiated neoplasm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Partial Response</title>
          <description>Response is defined by the Response Evaluation Criteria in Solid Tumor (RECIST). Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. For additional details about the RECIST criteria see the protocol Link module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2.3" upper_limit="25.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here are the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.</description>
        <time_frame>26 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belinostat</title>
            <description>1000 mg/m^2 day, 30 minute intravenous infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here are the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Chromosomal Gains or Losses in Comparative Genomic Hydridization in Thymoma and Thymic Cancer</title>
        <description>Utilize a patients tumor tissue to determine if there is any correlation between chromosomal gains or losses in comparative genomic hybridization in thymoma and thymic carcinomas and clinical outcomes.</description>
        <time_frame>46 months</time_frame>
        <population>Unpublished data from Dr. Giaccone's lab does not reveal an association between these parameters and outcomes in patients with thymic malignancies. Hence we do not plan to perform analyses for these outcome measures and there is no known negative clinical implications associated with this.</population>
        <group_list>
          <group group_id="O1">
            <title>Thymoma Patients</title>
            <description>Well differentiated neoplasm</description>
          </group>
          <group group_id="O2">
            <title>Thymic Patients</title>
            <description>Poorly differentiated neoplasm</description>
          </group>
        </group_list>
        <measure>
          <title>Chromosomal Gains or Losses in Comparative Genomic Hydridization in Thymoma and Thymic Cancer</title>
          <description>Utilize a patients tumor tissue to determine if there is any correlation between chromosomal gains or losses in comparative genomic hybridization in thymoma and thymic carcinomas and clinical outcomes.</description>
          <population>Unpublished data from Dr. Giaccone's lab does not reveal an association between these parameters and outcomes in patients with thymic malignancies. Hence we do not plan to perform analyses for these outcome measures and there is no known negative clinical implications associated with this.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 2 months</time_frame>
      <desc>CTCAE v3.0 from beginning of study through 12/31/10; CTCAE v4.0 beginning 1/1/11.</desc>
      <group_list>
        <group group_id="E1">
          <title>Belinostat Treatment</title>
          <description>1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)/CTCAE4</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations-Other, specify infection with normal ANC or Gr 1 or 2 neutrophils:Blood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)/CTCAE4</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="54" subjects_affected="27" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Right side abdominal pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="61" subjects_affected="23" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="22" subjects_affected="13" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <description>Facial swelling</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <description>Right lower extremity swelling</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Body aches</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Head/neck pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Left side</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Right side pain</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infections and infestations-Other, specify</sub_title>
                <description>HPV (Human papilloma virus)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <description>Pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" events="77" subjects_affected="21" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="92" subjects_affected="20" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="33" subjects_affected="14" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="55" subjects_affected="23" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <description>Right chest</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Back spasms</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>L arm</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>L thigh</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Right arm pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>shoulder</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Lightheaded</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <description>Metallic taste</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <description>Slurred speech</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <description>L arm</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <description>Numb right foot</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Peripheral sendory neuropathy</sub_title>
                <description>Tender skin</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <description>Hemoptysis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bronchopulomonary hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nail loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arun Rajan, M.D.</name_or_title>
      <organization>National Institutes of Health (NIH), National Cancer Institute (NCI)</organization>
      <phone>301-594-5322</phone>
      <email>rajana@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

